Inhibrx Biosciences said it has disclosed Phase 2 primary endpoint results for INBRX106 in first-line head and neck squamous cell carcinoma, but provided no efficacy data or trial specifics. The update keeps focus on its oncology pipeline.
published
Inhibrx Biosciences said it has disclosed Phase 2 primary endpoint results for INBRX106 in first-line head and neck squamous cell carcinoma, but provided no efficacy data or trial specifics. The update keeps focus on its oncology pipeline.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.